CLINICAL_TRIALS
trial_result
· 2021-09-05
Clinical Trial Update: A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite® [Phase 3]
Summary
Phase 3 trial examining Abilify MyCite in adults with schizophrenia was terminated; results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Schizophrenia | Phase 3 | Status: TERMINATED | Results posted: 2021-09-05